Inhibition of COX pathway in experimental myocardial infarction

Journal of Molecular and Cellular Cardiology
Takayuki SaitoA Giaid

Abstract

Release of inflammatory mediators within the ischemic myocardium has long been thought to contribute to myocardial damage and dysfunction. Myocardial infarction (MI) and congestive heart failure (CHF) were induced in rats by ligating the left coronary artery. Animals were treated with the selective cyclooxygenase-2 (COX-2) inhibitor-5,5-dimethyl-3-(3-fluorophenyl1)-4-(4-methyl-sulphonyl-2(5H)-fluranone (DFU), low-, high-dose acetyl salicylic acid (aspirin), or vehicle for 3 months. Strong immunoreactivity for COX-2 was detected in the cardiomyocytes, vascular endothelial cells, and macrophages in the infarcted myocardium. Compared to the vehicle, treatment with DFU significantly reduced left ventricular end-diastolic pressure, central venous pressure, lung wet/dry ratio and infarct size, and improved cardiac contractility (P < 0.05). In comparison, treatment with low or high doses of aspirin did not significantly impact any of these parameters. These findings demonstrate that induction of myocardial COX-2 in rats with CHF secondary to MI contributes to the cardiac injury and dysfunction associated with this disease, and that therapy aimed at inhibiting this enzymatic pathway at the onset of the disease may be beneficial in the ...Continue Reading

Citations

Dec 17, 2008·Cardiovascular Research·Christopher M JenkinsRichard W Gross
Mar 18, 2006·Apoptosis : an International Journal on Programmed Cell Death·A AbbateA Baldi
Sep 11, 2007·Apoptosis : an International Journal on Programmed Cell Death·Sévan KaloustianGuy Rousseau
May 5, 2012·Toxicology and Applied Pharmacology·Mabel CatalánGuillermo Díaz-Araya
Dec 17, 2008·Journal of Molecular and Cellular Cardiology·Javier InserteDavid Garcia-Dorado
Jan 4, 2012·Clinical and Experimental Pharmacology & Physiology·Ming ZhaoWei-Jin Zang
Sep 18, 2007·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Nina ZidarDusan Stajer
Apr 27, 2010·Veterinary Pathology·R S SellersN K Khan
Jun 15, 2007·Journal of Cardiovascular Pharmacology and Therapeutics·Guillermo SalinasYochai Birnbaum
Jan 26, 2018·Journal of Cardiovascular Development and Disease·John G KingmaChantale Simard
Feb 3, 2018·British Journal of Pharmacology·Shuaibo Huang, Nikolaos G Frangogiannis
Jun 20, 2007·Journal of Cardiovascular Pharmacology·Antonio AbbateRakesh C Kukreja
Jan 15, 2009·Angewandte Chemie·Stefan H Wunderlich, Paul Knochel
Nov 22, 2007·Journal of Cardiovascular Pharmacology·Stefania StrainoAntonio Abbate
Jun 17, 2009·Journal of Cardiovascular Pharmacology·Laura Lada-MoldovanGuy Rousseau
Apr 4, 2006·Current Opinion in Rheumatology·Stacy P Ardoin, John S Sundy
Sep 21, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Yi Zhun ZhuPhilip K Moore
Apr 7, 2009·Expert Opinion on Therapeutic Targets·Masahito OgawaMitsuaki Isobe
Mar 14, 2014·Journal of Cardiovascular Pharmacology·Yunzi MaPeiqing Liu
Jun 24, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Bochra Tourki, Ganesh Halade
May 13, 2006·Molecular and Cellular Biochemistry·Elena C LascanoJorge A Negroni
Jun 12, 2013·Molecular and Cellular Biochemistry·Nevena BarudzicVladimir Lj Jakovljevic
Jun 7, 2019·The Journal of Toxicological Sciences·Zaher A Radi, K Nasir Khan
Jan 8, 2020·JACC. Basic to Translational Science·Ricardo A GarcíaFrancisco J Villarreal
Apr 22, 2008·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Pandima Devi Sampath, Kannan Vijayaragavan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.